EU AI Act × GxP: what the AI Act means for regulated pharma quality

What the EU AI Act is — and what it is not

The EU AI Act (Regulation (EU) 2024/1689) is the EU's first comprehensive, horizontal AI regulation. Horizontal means it applies across industries to AI systems — not to pharma specifically, but to AI as a technology. It entered into force in 2024 and applies on a staggered timeline: prohibitions for certain practices already from early 2025, with the remaining core obligations phasing in across 2025, 2026 and 2027.

The Act takes a risk-based approach and broadly distinguishes four tiers — from prohibited practices, through strictly regulated applications and transparency obligations, to largely unregulated uses. It addresses different roles, in particular providers (who develop / place an AI system on the market) and deployers (who put it to use).

An important point first, to avoid misunderstanding: the AI Act is not a GxP rulebook and replaces neither GMP, nor EU Annex 11, nor 21 CFR Part 11. It sits alongside your existing quality and validation obligations. For regulated teams this is not a replacement, but a second perspective on the same AI tools.

Why the AI law concerns GxP teams at all

AI is entering regulated work — from document drafting through review support to data analysis. As soon as an AI system is used, it can in principle fall within the scope of the AI Act — in addition to the GxP requirements that already apply to the regulated activity.

The result is a double lens on the same tool: the GxP world asks “Is the work valid, traceable and released?” The AI Act asks “Is the AI system appropriately controlled, transparent and supervised?” Both questions aim at control and demonstrability — only from a different angle.

In practice this means: anyone using AI in GxP should not dismiss the AI Act perspective as a foreign topic, but consider it as a second governance layer — early, not only once an auditor or authority asks about it.

The good news: the governance principles overlap strongly

The reassuring insight for quality and validation teams: the core principles of both rulebooks run largely in parallel. Take GxP governance seriously and you have already built in much of the AI Act posture. The recurring themes:

• Human oversight. The AI Act stresses human control over AI outputs; GxP requires human release anyway. The same idea: the AI proposes, the human decides.
• Transparency & traceability. Both want to know how a result came about — sources, basis, traceability instead of a black box.
• Data governance. Quality, origin and suitability of the data used is a topic in both worlds.
• Logging & records. The AI Act thinks in logs and demonstrability; GxP in audit trail and records. Structurally the same need.
• Risk management & accountability. Both require a deliberate look at risk and clear ownership of who is responsible for what.

In other words: a robust GxP way of working — sources first, AI as a suggestion, human release, a connected audit trail — feeds directly into the AI Act's governance expectations too. That is not a coincidence, but the same control logic in two rulebooks.

Take GxP governance seriously and you have already built in much of the AI Act posture.

Where the frameworks differ — and why you should not classify finally yourself

As large as the overlap is in principle, the rulebooks are not congruent:

• Own scope and own definitions. The AI Act has its own terms (e.g. “AI system”, provider vs. deployer) and its own scope, which cannot be derived 1:1 from the GxP world.
• Own risk taxonomy. The AI Act's risk tiers follow a different logic than GxP risk assessment (patient safety / product quality). A GxP classification is not an AI Act classification.
• Role-dependent obligations. Whether you count as a provider or a deployer changes the obligations considerably — and depends on how you concretely use or provide an AI system.
• Staggered, still maturing application. Parts of the Act apply only over time; accompanying guidelines and harmonized standards keep evolving.

This is exactly why the classification of a specific system is a legal question, not a marketing or gut-feel decision. The serious approach is to understand the interface, make the preparation that is sensible anyway — and settle the classification with qualified legal advice.

What you can practically do now — without waiting for the final legal picture

The good message: the most effective preparation is classification-independent. It is good GxP practice and at the same time AI-Act-compatible — you can start it before the legal picture is settled:

• Keep an AI inventory. Where is AI actually used in regulated work today — and for what purpose? No overview, no control.
• Secure human release. For every GxP-relevant AI output, the professional review and named release remain mandatory. AI prepares, AI does not release.
• Carry the source binding and audit trail. Every relevant statement stays connected to its source and version; who decided what on which basis stays traceable.
• Document data governance. Which data may the AI use, where does it come from, what is excluded?
• Name responsibilities. Who is accountable for use, monitoring and stopping an AI tool?

None of these points weaken your GxP compliance — they reinforce it and at the same time create the substance an eventual AI Act assessment can build on. This is exactly the way of working traqx reflects: AI drafts, your team reviews and releases, sources/versions/audit trail stay connected — Generate. Verify. Monitor. That is a control architecture, not a compliance promise.

The honest limits

Finally, the necessary sobriety:

• This is not legal advice. The contextualization does not replace an assessment of your specific scope by qualified legal counsel.
• No risk classification. This article classifies neither traqx nor your applications into an AI Act risk tier — that is deliberately reserved for legal assessment.
• The framework keeps maturing. Application, guidelines and harmonized standards are evolving; statements made today are a snapshot.
• GxP remains in force. The AI Act complements, but does not replace, GMP, Annex 11 or Part 11. Both layers apply side by side.